Fredun Pharmaceuticals gains on launching Hormone Range Products
Fredun Pharmaceuticals is currently trading at Rs. 2344.50, up by 41.95 points or 1.82% from its previous closing of Rs. 2302.55 on the BSE.
The scrip opened at Rs. 2326.05 and has touched a high and low of Rs. 2399.00 and Rs. 2326.05 respectively. So far 3260 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 2550.00 on 11-May-2026 and a 52 week low of Rs. 690.00 on 02-Jun-2025.
Last one week high and low of the scrip stood at Rs. 2,550.00 and Rs. 1,820.00 respectively. The current market cap of the company is Rs. 1,276.83 crore.
The promoters holding in the company stood at 44.17%, while Institutions and Non-Institutions held 3.89% and 51.94% respectively.
Fredun Pharmaceuticals has launched Hormone Range Products, its premium specialty therapeutics brand focused on longevity, hormone health, recovery science, and human performance solutions. The initiative marks Fredun’s strategic entry into a rapidly expanding, high-value healthcare segment driven by increasing global demand for preventive, performance-oriented, and precision-based therapeutics.
Built on a doctor-led, ethical, and evidence-backed pharmaceutical model, the hormone range products combine clinical credibility with a digital-first patient / doctor engagement ecosystem to deliver an integrated healthcare experience focused on outcomes, adherence, and long-term patient value. The range is designed to address the growing shift from traditional disease management towards healthy lifespan optimization, preventive care, and advanced performance therapeutics.
The initial portfolio includes therapies and formulations based on testosterone and its salts, nandrolone, growth hormone-oriented solutions, and supportive hormone optimization therapies, developed to meet specialised clinical requirements under appropriate medical supervision. The platform is further supported by protocol-driven patient monitoring, doctor engagement, and direct-to-patient fulfilment capabilities designed to improve treatment continuity and patient adherence. The brand leverages Fredun Pharmaceuticals’ established strengths in pharmaceutical formulation development, quality-focused manufacturing, and global distribution capabilities, while creating new opportunities in premium, innovation-driven therapeutic segments.
